ToxGenSolutions Zeroes in on microRNA for the Early Detection of Alzheimer’s
The Dutch company has created a device that can detect early signs of Alzheimer’s, and they’re on their way to developing a preventative drug.
Investors, learn how you can become a Health Moonshot Champion and support Health Transformers like Drs Erwin Roggen and Maria Tsamou.
Origin Story
In 2019 Maria Tsamou, PhD, the Chief Scientific Officer at ToxGenSolutions, obtained human blood samples at a Greek hospital from people with mild cognitive impairments to test for a microRNA profile that her team thought might be associated with the early onset of Alzheimer's disease (AD). All the results from her tests of the experimental group were positive – but she also got positive Alzheimer’s results from almost half of the control group, who were considered healthy during the visit. They were discouraged by what they saw as false positives in the control group and felt the experiment was a failure. Then Tsamou, in an effort to get greater clarity, discussed the results with a professor working with the same group of patients. She learned that there were early samples available from the same group taken during a four-year study. It turned out that a meaningful percentage of the seemingly healthy patients who had tested positive for Alzheimer’s in the control group had gone on to develop full Alzheimer’s disease. Their diagnostic tool had worked after all and better than expected.
“We opened up a bottle of champagne and started celebrating the success,” says Erwin Roggen, PhD, CEO & Co-founder of ToxGenSolutions. “We believed we were doing the right thing,” he says. “That’s how it picked up.”
The Challenge
ToxGenSolutions started with the hypothesis that an AD diagnosis happens far too late for any meaningful intervention. “By the time people are diagnosed with AD their brain looks like Swiss cheese,” says Roggen. He describes the process of a typical AD diagnosis: a patient experiencing forgetfulness usually begins with a questionnaire administered by a physician, which results in a score that might provide a diagnosis of cognitive impairment. Typically, a patient is asked to return a few months later for a follow-up appointment, which can sometimes stretch into a year. Eventually, when the physician is confident that something is wrong, a lumbar puncture is administered to test for proteins in the patient’s cerebrospinal fluid. If the results are positive the patient then undergoes MRI or PET scans. “It can take a year or two before one is actually diagnosed,” says Roggen.
The Solution
ToxGenSolutions is developing a diagnostic device that can measure microRNAs in a drop of blood and identify signs of AD within moments. In addition, it can anticipate the disease six years before onset, and they’re hoping they can move that window to 10 or 15 years before onset.
They are not stopping at the development of just this device, which will be submitted to medical agencies for approval later this year. Roggen leads an international team based in the Netherlands focused on three major goals: early detection of AD, production of a device for doing so, and administration of a therapy.
“We want to use our insight from the diagnostics and the computational part, first, to identify patients as soon as possible, and then to develop potential preventative drugs,” says Roggen. “It doesn't make sense to have an early diagnosis if you don't have any drug to treat it.”
How It Works: Early Detection of Alzheimer's Disease
MicroRNAs are small molecules that exist within genes or between genes and can fine-tune their expression. When a chemical from an environmental factor hits a cell, both the genes and the microRNAs are affected, resulting in either an upregulation or downregulation of the gene.
Whereas one’s genes and chromosomes are fixed, microRNAs are expressed in a moment and are constantly changing. ToxGenSolutions zeroed in on microRNA as a key arbiter between genes and environmental chemicals, responsible for the onset of a disease like Alzheimer’s, which is caused by the interplay between genetic and environmental factors. “AD is not a problem of pathologic genes, but dysregulated genes,” says Roggen.
Early in their research, ToxGenSolutions found some microRNA molecules that were only present in patients with mild cognitive impairments and were different from the microRNA molecules present in Alzheimer’s patients.
With their device, they can analyze blood, tears, or hypodermal fluid for their microRNA patterns that they have associated with early cognitive decline and confidently predict whether or not a person will develop mild cognitive impairment or Alzheimer’s disease.
How It Works: Developing a Drug
Now that ToxGenSolutions has discovered a microRNA profile associated with pre-Alzheimer’s disease, they are considering how to hack into the processes and pathways between microRNAs and genes. They’re looking at the impact of environmental chemicals with the hopes of using a drug to control the interplay between microRNA and gene expression.
They are convinced that their solution is an improvement on models of therapy that use stem cells or monoclonal antibodies. “We could do what they did with Parkinson's disease years ago where they injected stem cells and saw an improvement but then the cells started dying, of course, because if you don’t remove the reason why the original cells are dying, new cells will die as well,” says Roggen.
Furthermore, Roggen sees the monoclonal antibody approach, often favored by pharmaceutical companies, as risky. “With Alzheimer’s disease and dementia in general and so many other chronic diseases, chronic inflammation is a driver. It’s a risk factor to add an antibody onto a cluster of proteins or a bacteria or virus because the first thing that happens is an inflammatory response that starts the immune response,” says Roggen.
“We want to work with a chemical solution that will pass the blood-brain barrier and not trigger an inflammatory response,” says Roggen. They are encouraged by developments in cancer research where microRNA therapy is being used to stop processes and kill cancer cells.
Where They Are in the Process
Although ToxGenSolutions has already developed a diagnostic device for identifying a microRNA profile associated with the development of Alzheimer’s disease, they are still on a journey toward creating a drug to prevent AD. “We have identified model drug targets, and we are putting them in a computer system and screening them against 50,000 chemicals,” says Roggen. Many of these chemicals are repurposed, including chemicals that may have been on the market and tested in clinical trials but didn’t work as expected.
ToxGenSolutions has an agreement with an Australian company that has human brain organoids, which bring together human brain cells in a 3D structure. They will use this to test whether their chemicals are toxic. For the drugs that they determine to be safe and non-toxic, ToxGenSolutions will take them apart and induce neurodegeneration with environmental chemicals. “Then we will give the drug and see if it can stop and preferably reverse the process,” says Roggen. Once they have a drug, they’re confident that it will be immediately effective. “MicroRNAs react within 30 minutes after you introduce a drug,” says Roggen. They expect to reach this milestone by 2028 at the earliest.
Our Take
ToxGenSolutions is an ambitious company already on the path to tackling Alzheimer’s disease. Their diagnostic tool could radically reduce the timeline of diagnosis and create opportunities for early treatment. Their research around microRNA therapy shows promise at altering the underlying causes of Alzheimer’s by targeting the interaction between genes and environmental chemicals. Furthermore, their ambitions extend beyond AD. They are building a database with the microRNAs of all diseases with a chronic vector, like Alzheimer’s and Parkinson’s. “We’re building a very big network to show the interaction and pathways between microRNAs, genes and different diseases,” says Roggen. “It is our dream to find the one golden bullet that can address all these chronic diseases.”
Join us in welcoming the ToxGenSolutions team to StartUp Health’s Alzheimer’s Moonshot Community.
Connect with ToxGenSolutions via email
Call for Alzheimer’s Innovation
With support from the Alzheimer’s Drug Discovery Foundation (ADDF) and Gates Ventures, we’ve launched a new global initiative created to develop a collaborative innovation community alongside leading companies, research teams, and stakeholders with a mission to accelerate progress in prevention, diagnosis, and management of Alzheimer’s disease and related dementias. Learn more and apply for an Alzheimer’s Moonshot Fellowship.
Become a Health Moonshot Champion
Health moonshots are fueled by passionate families, foundations, and industry organizations committed to achieving health moonshots. Learn how you can join other champions of the T1D Moonshot or one of our other global health moonshots.
Follow us on social media for daily updates on Health Transformers: Twitter, LinkedIn, Facebook, and Instagram.
Published: Jun 6, 2024